CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker

This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.PMID:37713234 | DOI:10.2217/bmm-2023-0202
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Authors: Source Type: research